Company Quick10K Filing
Dexcom
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 91 $12,908
10-K 2020-02-13 Annual: 2019-12-31
10-Q 2019-11-06 Quarter: 2019-09-30
10-Q 2019-07-31 Quarter: 2019-06-30
10-Q 2019-05-01 Quarter: 2019-03-31
10-K 2019-02-21 Annual: 2018-12-31
10-Q 2018-11-06 Quarter: 2018-09-30
10-Q 2018-08-01 Quarter: 2018-06-30
10-Q 2018-05-02 Quarter: 2018-03-31
10-K 2018-02-27 Annual: 2017-12-31
10-Q 2017-11-01 Quarter: 2017-09-30
10-Q 2017-08-01 Quarter: 2017-06-30
10-Q 2017-05-02 Quarter: 2017-03-31
10-K 2017-02-28 Annual: 2016-12-31
10-Q 2016-11-01 Quarter: 2016-09-30
10-Q 2016-08-02 Quarter: 2016-06-30
10-Q 2016-04-27 Quarter: 2016-03-31
10-K 2016-02-23 Annual: 2015-12-31
10-Q 2015-11-04 Quarter: 2015-09-30
10-Q 2015-08-05 Quarter: 2015-06-30
10-Q 2015-04-29 Quarter: 2015-03-31
10-K 2015-02-25 Annual: 2014-12-31
10-Q 2014-11-06 Quarter: 2014-09-30
10-Q 2014-08-06 Quarter: 2014-06-30
10-Q 2014-05-01 Quarter: 2014-03-31
10-K 2014-02-20 Annual: 2013-12-31
10-Q 2013-11-06 Quarter: 2013-09-30
10-Q 2013-08-07 Quarter: 2013-06-30
10-Q 2013-05-01 Quarter: 2013-03-31
10-K 2013-02-21 Annual: 2012-12-31
10-Q 2012-11-01 Quarter: 2012-09-30
10-Q 2012-05-02 Quarter: 2012-03-31
10-K 2012-02-23 Annual: 2011-12-31
10-Q 2011-11-02 Quarter: 2011-09-30
10-Q 2011-08-03 Quarter: 2011-06-30
10-Q 2011-05-03 Quarter: 2011-03-31
10-K 2011-03-03 Annual: 2010-12-31
10-Q 2010-11-04 Quarter: 2010-09-30
10-Q 2010-08-03 Quarter: 2010-06-30
10-Q 2010-05-05 Quarter: 2010-03-31
10-K 2010-03-09 Annual: 2009-12-31
8-K 2020-02-13 Earnings, Exhibits
8-K 2020-01-13 Earnings, Exhibits
8-K 2019-11-06 Earnings, Exhibits
8-K 2019-09-13 Officers, Other Events, Exhibits
8-K 2019-07-31 Earnings, Exhibits
8-K 2019-06-04 Officers, Shareholder Vote, Exhibits
8-K 2019-05-01 Earnings, Exhibits
8-K 2019-04-24 Officers
8-K 2019-02-21 Earnings, Exit Costs, Exhibits
8-K 2019-01-07 Earnings, Exhibits
8-K 2018-12-19 Enter Agreement, Off-BS Arrangement
8-K 2018-11-30 Enter Agreement, Off-BS Arrangement, Sale of Shares, Other Events, Exhibits
8-K 2018-11-28 Other Events, Exhibits
8-K 2018-11-26 Other Events, Exhibits
8-K 2018-11-20 Enter Agreement, Exhibits
8-K 2018-11-06 Earnings, Exhibits
8-K 2018-08-01 Earnings, Exhibits
8-K 2018-07-30 Officers, Exhibits
8-K 2018-05-31 Shareholder Vote
8-K 2018-05-02 Earnings, Exhibits
8-K 2018-03-08 Officers
8-K 2018-02-27 Earnings, Exhibits
8-K 2018-01-08 Earnings, Exhibits
8-K 2018-01-08 Earnings, Regulation FD, Exhibits

Dexcom Financials

DXCM Metrics, Comps, Filings

Annual | Quarterly

Business

We are a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring, or CGM, systems for use by people with diabetes and by healthcare providers. We received approval from the United States (U.S.) Food and Drug Administration, or FDA, and commercialized our first product in 2006. We launched our latest generation system, the DexCom G6® integrated Continuous Glucose Monitoring System, or G6, in 2018. Unless the context requires otherwise, the terms "we," "us," "our," the "company," or "DexCom" refer to DexCom, Inc. and its subsidiaries.

In March 2018, we obtained marketing authorization from the FDA for the G6 via the de novo process. The G6 is the first type of continuous glucose monitoring system permitted by the FDA to be used as part of an integrated system with other compatible medical devices and electronic interfaces, which may include automated insulin dosing systems, insulin pumps, blood glucose meters or other electronic devices used for diabetes management. G6 and substantially equivalent devices of this generic type that may later receive marketing authorization are referred to as integrated continuous glucose monitoring systems or iCGMs, and have been classified as Class II devices. Along with this classification, the FDA established criteria, called special controls, which outline requirements for assuring CGM accuracy, reliability and clinical relevance, and which also describe the type of studies and data required to demonstrate acceptable CGM performance.

The G6 is designed to allow our transmitter to run an algorithm to generate a glucose value and to communicate directly to a patient's compatible mobile device, including iPhone®, iPod touch®, iPad®, and certain Android® mobile devices. A patient's glucose data can also be displayed on wearable devices, like the Apple Watch® and Wear OS by Google devices. The G6 transmitter has a labeled useful life of three months. Data from the G6 can be integrated with DexCom CLARITY®, our cloud-based reporting software, for personalized, easy-to-understand analysis of trends that may improve diabetes management. In June 2018, we received Conformité Européenne Marking, or CE Mark, approval for the G6, which allows us to market the system in the European Union and the countries in Asia and Latin America that recognize the CE Mark, as well as New Zealand (subject to compliance with certain local administrative requirements) though certain countries may require additional marketing authorizations (for example, the inclusion of medical devices on the Australian Register of Therapeutic Goods in Australia).


Valuation ($BB)

Market Cap, Enterprise Value

Balance Sheet ($BB)

Assets, Stockholders' Equity

Income Statement ($BB Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($BB Annual)

Operating, Investing, Financing

Comps ($MM TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
ResMed (RMD) 17,425 59% 21.9 10% 4,108 2,035 2,607 1,537 405 848 18,540
Teleflex (TFX) 15,750 57% 29.3 4% 6,314 3,650 2,521 1,426 271 600 17,595
Dentsply Sirona (XRAY) 13,003 52% 29.7 1% 8,575 3,392 3,944 2,041 105 478 14,194
Dexcom (DXCM) 12,908 63% -140.0 -8% 2,066 1,378 1,222 767 -170 -87 12,198
ABIOMED (ABMD) 11,806 83% 35.8 23% 1,125 122 797 661 258 327 11,705
Insulet (PODD) 7,136 66% 163.9 2% 978 728 661 435 17 47 7,624
Hill-Rom Holdings (HRC) 7,067 49% 25.9 5% 4,575 2,951 2,884 1,415 215 335 8,663
Haemonetics (HAE) 6,085 46% 35.9 4% 1,260 669 977 450 49 176 6,331
Penumbra (PEN) 6,047 67% 257.6 3% 585 131 495 332 15 23 5,969
Novocure (NVCR) 5,679 72% -357.0 -10% 406 247 294 212 -41 -16 5,646
ICU Medical (ICUI) 5,345 39% 39.5 3% 1,623 305 1,311 508 47 127 5,031
Integra Lifesciences (IART) 4,669 62% 20.6 3% 3,290 1,869 1,493 930 101 262 5,393
Globus Medical (GMED) 4,300 77% 18.9 10% 1,391 103 743 573 143 221 4,182
Cantel Medical (CMD) 3,630 47% 30.3 5% 1,070 409 918 427 55 126 3,816
Tandem Diabetes Care (TNDM) 3,601 52% -70.5 -22% 255 110 282 147 -55 -49 3,470
Merit Medical Systems (MMSI) 3,357 45% 26.4 2% 1,736 786 949 423 39 141 3,722
Nuvasive (NUVA) 3,283 72% 19.4 3% 1,805 1,127 814 52 194 3,765
Glaukos (GKOS) 2,779 87% -384.5 -4% 302 114 211 182 -12 -7 2,730
Nevro (NVRO) 1,957 69% -26.5 -21% 448 246 379 261 -93 -77 2,049
iRhythm Technologies (IRTC) 1,941 75% -48.5 -21% 207 159 182 137 -44 -40 1,923

Balance Sheet ($MM)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash115584115945490
Accounts Receivable1320264274102134227
Inventory8791635454571
PP&E1519473155109146183
Assets1201061221852924039041,916
Accounts Payable441019244776
Long-Term Debt775
Liabilities16293844711194851,253
Stockholders' Equity
Income Statement ($MM)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Revenue66931572574015737181,032
Cost of Revenue40536083124195226368
Gross Profit3647100176278378492664
R&D31404569138156185200
SG&A506384128198286349433
Tax-0-1000021
Net Income-45-54-30-22-58-66-50-127
Cash Flow ($MM)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash Operating-30-33224495692123
Cash Investing-462821-17-52-56-144-140
Cash Financing74101222178399710